Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has reported Other Non-Current Liabilities for 4 consecutive years, with $950000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 32.14% year-over-year to $950000.0 in Q2 2026; TTM through Jun 2026 was $950000.0, a 32.14% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, changed N/A from the prior year.
• Other Non-Current Liabilities was $950000.0 for Q2 2026 at Vivos Therapeutics, down from $1.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.2 million in Q2 2023 and troughed at $101000.0 in Q1 2022.
• A 4-year average of $1.2 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities soared 1219.8% in 2023 and slumped 32.14% in 2026, its largest moves.
• Over 4 years, Other Non-Current Liabilities stood at $101000.0 in 2022, then surged by 494.06% to $600000.0 in 2023, then jumped by 116.67% to $1.3 million in 2025, then decreased by 26.92% to $950000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $950000.0 (Q2 2026), $1.3 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.